PRGO

#2163
Perrigo Company plc Ordinary Shares
11.1 1 USD
+9586.14%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
11.05
11.24
Range Annuel
0.11
22.01
Changement quotidien
+9586.14%
Changement Mensuel
-1.86%
Evolution sur 6 mois
-16.53%
Changement Annuel
-48.37%
Clôture Précédente
0.1 1
Open
11.0 8
Low
11.0 5
High
11.2 4
Volume
75
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 1.54 B
  • Employee 8 100
  • Founded N/A
  • CEO Murray S. Kessler
  • Website www.perrigo.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Fabricants de Médicaments — Spécialités et Génériques
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-1.35
ratio cours/chiffre d'affaires
0.45
Dividende par action
1.16
Rendement du dividende (%)
8.33

Perrigo Company plc Ordinary Shares

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.

Nouvelles